Siemens Healthineers: Two Businesses, One Trust Problem

Investor skepticism mounts as Siemens Healthineers' diagnostics division drags down earnings, with shares near 52-week lows despite a solid imaging business and a €230M buyback.

Siemens Healthineers has spent the past weeks on an intensive investor roadshow, but the message from management is struggling to break through a wall of skepticism. The stock, trading near €34.35, has shed more than 22% since January and sits just a few percent above its 52-week low of €32.84. The problem is not a general operational meltdown — it is a stark divergence between two halves of the business that investors are finding harder to reconcile.

The core imaging division, which accounts for the lion's share of profits, keeps churning out solid numbers: comparable sales growth of 6.1% and an operating margin of 22.4%. Precision Therapy is also performing well. But diagnostics, the segment that was supposed to be a growth engine, has become a millstone. Revenues shrank 6.5% in the latest quarter, and the adjusted margin collapsed to a wafer-thin 0.9%. Structural market changes in China, combined with roughly €400 million in tariff-related costs and adverse currency movements, are squeezing the division from multiple angles.

Management responded by slashing the full-year 2026 outlook. Revenue growth is now seen at 4.5% to 5.0%, down from a prior target of up to 6%. Earnings per share are forecast at €2.20 to €2.30 — a noticeable step down. The balance sheet adds another layer of unease: net debt has climbed to €13.2 billion, or 3.1 times operating earnings.

To shore up confidence, the company launched a €230 million share buyback program in early June, set to run through January 2027. In the second week alone it repurchased nearly 453,000 shares, mainly for employee compensation plans. Yet with a market capitalisation of €39.4 billion, the buyback is more of a gesture than a game-changer. It creates a floor of demand but cannot substitute for operational clarity.

The technical picture does not offer much comfort either. The stock languishes below both its 50-day and 200-day moving averages — the latter sits at around €41.40, more than 20% above the current price. The relative strength index of 44 suggests selling pressure has moderated, but there is no sign of a panic-driven oversold bounce. Annualised volatility of 21% points to a jittery market, not a full-blown crisis.

The constructive argument rests on the resilience of imaging and the long-term value of the core franchise. A recent order from the University Heart & Vascular Center at the UKE in Hamburg, which includes new imaging equipment and a multi-year research partnership in cardiology and radiology, underscores that hospitals still need precision and efficiency. But that alone will not turn the stock around. Until management can demonstrate that diagnostics has truly bottomed out in China and that margins are on a credible recovery path, the trust deficit will persist. The next milestone is the third-quarter report on July 31 — a date investors have circled with equal parts hope and caution.